IXICO Targets Go-To Status In Neuro Data Analytics Space

Neuroscience data specialist IXICO has broad ambitions to partner with pharmas large and small, helping them develop better-targeted clinical trials using imaging and digital biomarker data. A business review in late 2017 by CEO Giulio Cerroni refined the company’s value proposition, while keeping the headline elements in place: scale the business and diversify within neuroscience.

Cerroni_Giulio
IXICO CEO Giulio Cerroni

The neuroscience data analytics company Ixico Ltd. is many things to many people, but it is not a start-up. CEO of two years Giulio Cerroni stresses that almost before we start. IXICO is also not an especially young company, formed some 14 years ago as a spin-out from several UK universities, it has been trading for 13 years, and in 2018 (year-end September 30) reported an underlying revenue increase of 41% and a record-high revenue total of £5.4m ($7.02m). It has been AIM-listed since its 2013 reverse takeover of Phytopharm.

The company’s performance to date has been good, but it is not good enough for Cerroni. On assuming the chief...

More from Innovation

When Simple Is Best: A Pre-Term Birth Device To End The ‘Silent Emergency’

 
• By 

The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By 

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Trojan Bio Eyes Perfect Rainbow Shot With Immune System Cancer Innovations

 
• By 

Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

More from In Vivo

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By 

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By 

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.